Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

ESTUDIOS


01 agosto 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Complete Revascularization Is Not a Prerequisite for Success in Current Transcatheter Aortic Valve Implantation Practice

Nicolas M. Van Mieghem, MD∗; Robert M. van der Boon, MSc∗; Elhamula Faqiri, MSc∗; Roberto Diletti, MD∗; Carl Schultz, MD, PhD∗; Robert-Jan van Geuns, MD, PhD∗; Patrick W. Serruys, MD, PhD∗; Arie-Pieter Kappetein, MD, PhD†; Ron T. van Domburg, PhD∗; Peter P. de Jaegere, MD, PhD∗

Objectives: This study sought to assess in patients undergoing transcatheter aortic valve implantation (TAVI), the prevalence and impact of incomplete coronary revascularization defined as >50% coronary artery or graft diameter stenosis on visual assessment of the coronary angiogram.

01 agosto 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Survival After Endovascular Therapy in Patients With Type B Aortic Dissection. A Report From the International Registry of Acute Aortic Dissection (IRAD)

Rossella Fattori, MD∗; Daniel Montgomery, BS†; Luigi Lovato, MD‡; Stephan Kische, MD§; Marco Di Eusanio, MD‡; Hüseyin Ince, MD§; Kim A. Eagle, MD†; Eric M. Isselbacher, MD⋮; Christoph A. Nienaber, MD§

Objectives: This study sought to evaluate long-term survival in type B aortic dissection patients treated with thoracic endovascular aortic repair (TEVAR) therapy.

01 agosto 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Tissue Uptake, Distribution, and Healing Response After Delivery of Paclitaxel via Second-Generation Iopromide-Based Balloon Coating

Piotr P. Buszman, MD, PhD∗; Armando Tellez, MD∗; Maxwell E. Afari, MD∗; Athanasios Peppas, MS∗; Gerard B. Conditt, RCIS∗; Serge D. Rousselle, DVM†; Jennifer C. McGregor, BS∗; Mark Stenoien, MS‡; Greg L. Kaluza, MD, PhD∗; Juan F. Granada, MD∗

Objectives: This study sought to evaluate vascular drug uptake, distribution and response of second-generation paclitaxel coated balloon (PCB) (Cotavance, MEDRAD Interventional, Indianola, Pennsylvania) and compare it with first-generation technology, containing identical excipient and drug concentration.

19 febrero 2014

EUROPEAN HEART JOURNAL. Perioperative risk of major non-cardiac surgery in patients with severe aortic stenosis: a reappraisal in contemporary practice

Teruko Tashiro, Sorin V. Pislaru, Jodi M. Blustin, Vuyisile T. Nkomo, Martin D. Abel, Christopher G. Scott, Patricia A. Pellikka

Aims: Severe aortic stenosis (SAS) is a major risk factor for death after non-cardiac surgery, but most supporting data are from studies over a decade old. We evaluated the risk of non-cardiac surgery in patients with SAS in contemporary practice.

21 julio 2014

EUROPEAN HEART JOURNAL. CardioPulse Articles. New oral anticoagulants for non-valvular atrial fibrillation: harder to handle than expectedOnce-daily edoxaban: a safer option than well-managed warfarin for patients with atrial fibrillation?The Quick Test: 80 years onApixaban: a new direct oral anticoagulant for stroke prevention in atrial fibrillationNovel oral anticoagulants in the emergency room

Barry Shurlock, PhD

Many clinicians who manage coagulation therapy have long had a love–hate relationship with the vitamin K antagonist warfarin. The complexity of its use, the intricacies of INR—as well as its use as a rat poison!—have also done little to endear it to patients.

21 febrero 2014

EUROPEAN HEART JOURNAL. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial

Sigrun Halvorsen, Dan Atar, Hongqiu Yang, Raffaele De Caterina, Cetin Erol, David Garcia, Christopher B. Granger, Michael Hanna, Claes Held, Steen Husted, Elaine M. Hylek, Petr Jansky, Renato D. Lopes, Witold Ruzyllo, Laine Thomas, Lars Wallentin

Aims: The risk of stroke in patients with atrial fibrillation (AF) increases with age. In the ARISTOTLE trial, apixaban when compared with warfarin reduced the rate of stroke, death, and bleeding. We evaluated these outcomes in relation to patient age.

21 marzo 2013

EUROPEAN HEART JOURNAL. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial

Jonathan P. Piccini, Jyotsna Garg, Manesh R. Patel, Yuliya Lokhnygina, Shaun G. Goodman, Richard C. Becker, Scott D. Berkowitz, Günter Breithardt, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Christopher C. Nessel, Kenneth W. Mahaffey, Daniel E. Singer, Robert M. Califf, Keith A. A. Fox,

Aims: There are no data regarding management and outcomes of major bleeding events in patients treated with oral factor Xa inhibitors.

01 junio 2014

EUROPEAN HEART JOURNAL. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry

Jan Beyer-Westendorf, Vera Gelbricht, Kati Förster, Franziska Ebertz, Christina Köhler, Sebastian Werth, Eberhard Kuhlisch, Thoralf Stange, Christoph Thieme, Katharina Daschkow, Norbert Weiss

Aims: Patients receiving novel oral anticoagulants (NOACs) frequently undergo interventional procedures. Short half-lives and rapid onset of action allow for short periods of NOAC interruption without heparin bridging. However, outcome data for this approach are lacking. We evaluated the peri-interventional NOAC management in unselected patients from daily care.

13 marzo 2014

EUROPEAN HEART JOURNAL. Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type

Edoardo Camenzind, Eric Boersma, William Wijns, Laura Mauri, Tessa Rademaker-Havinga, Farzin Fath Ordoubadi, Maarten J. Suttorp, Mohammad Al Kurdi, Ph Gabriel Steg,

Aim: To investigate the putative modifying effect of dual antiplatelet therapy (DAPT) use on the incidence of stent thrombosis at 3 years in patients randomized to Endeavor zotarolimus-eluting stent (E-ZES) or Cypher sirolimus-eluting stent (C-SES).

12 abril 2014

EUROPEAN HEART JOURNAL. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial

Daniel Lindholm, Christoph Varenhorst, Christopher P Cannon, Robert A Harrington, Anders Himmelmann, Juan Maya, Steen Husted, Philippe Gabriel Steg, Jan H Cornel, Robert F Storey, Susanna R Stevens, Lars Wallentin, Stefan K James

Aims: The optimal platelet inhibition strategy for ACS patients managed without revascularization is unknown.

20 febrero 2013

EUROPEAN HEART JOURNAL. The rationale for Heart Team decision-making for patients with stable, complex coronary artery disease

Stuart J. Head, Sanjay Kaul, Michael J. Mack, Patrick W. Serruys, David P. Taggart, David R. Holmes, Martin B. Leon, Jean Marco, Ad J.J.C. Bogers, A. Pieter Kappetein

Abstract: Stable complex coronary artery disease can be treated with coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), or medical therapy. Multidisciplinary decision-making has gained more emphasis over the recent years to select the most optimal treatment strategy for individual patients with stable complex coronary artery disease. However, the so-called ‘Heart Team’ concept has not been widely implemented. Yet, decision-making has shown to remain suboptimal; there is large variability in PCI-to-CABG ratios, which may predominantly be the consequence of physician-related factors that have raised concerns regarding overuse, underuse, and inappropriate selection of revascularization. In this review, we summarize these and additional data to support the statement that a multidisciplinary Heart Team consisting of at least a clinical/non-invasive cardiologist, interventional cardiologist, and cardiac surgeon, can together better analyse and interpret the available diagnostic evidence, put into context the clinical condition of the patient as well as consider individual preference and local expertise, and through shared decision-making with the patient can arrive at a most optimal joint treatment strategy recommendation for patients with stable complex coronary artery disease. In addition, other aspects of Heart Team decision-making are discussed: the organization and logistics, involvement of physicians, patients, and assisting personnel, the need for validation, and its limitations.

01 septiembre 2013

JACC. The STS-ACC Transcatheter Valve Therapy National Registry

John D. Carroll, MD∗; Fred H. Edwards, MD†; Danica Marinac-Dabic, MD, PhD‡; Ralph G. Brindis, MD, MPH§; Frederick L. Grover, MD∗; Eric D. Peterson, MD, MPH‖; E. Murat Tuzcu, MD¶; David M. Shahian, MD#; John S. Rumsfeld, MD, PhD∗∗; Cynthia M. Shewan, PhD††; Kathleen Hewitt, MSN, RN‡‡; David R. Holmes, MD§§; Michael J. Mack, MD‖‖

Abstract: The Society of Thoracic Surgeons (STS) and American College of Cardiology (ACC) transcatheter valve therapy (TVT) registry is a novel, national registry for all new TVT devices created through a partnership of the STS and the ACC in close collaboration with the Food and Drug Administration, the Center for Medicare and Medicaid Services, and the Duke Clinical Research Institute. The registry will serve as an objective, comprehensive, and scientifically based resource to improve the quality of patient care, to monitor the safety and effectiveness of TVT devices, to serve as an analytic resource for TVT research, and to enhance communication among key stakeholders.

01 septiembre 2013

JACC. Oral Anticoagulation and Antiplatelets in Atrial Fibrillation Patients After Myocardial Infarction and Coronary Intervention

Morten Lamberts, MD∗; Gunnar H. Gislason, MD, PhD∗; Jonas Bjerring Olesen, MD∗; Søren Lund Kristensen, MD∗; Anne-Marie Schjerning Olsen, MD∗; Anders Mikkelsen, MB∗; Christine Benn Christensen, MD∗; Gregory Y.H. Lip, MD†; Lars Køber, MD, DMS‖; Christian Torp-Pedersen, MD, DMS∗; Morten Lock Hansen, MD, PhD∗

Objectives: The purpose of this study was to investigate the risk of thrombosis and bleeding according to multiple antithrombotic treatment regimens in atrial fibrillation (AF) patients after myocardial infarction (MI) or percutaneous coronary intervention (PCI).

01 agosto 2013

JACC. Clinical Outcomes With Drug-Eluting and Bare-Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction

Tullio Palmerini, MD∗; Giuseppe Biondi-Zoccai, MD†; Diego Della Riva, MD∗; Andrea Mariani, MD∗; Manel Sabaté, MD‡; Marco Valgimigli, MD§; Giacomo Frati, MD†; Elvin Kedhi, MD⋮; Pieter C. Smits, MD⋮; Christoph Kaiser, MD¶; Philippe Genereux, MD#; Soren Galatius, MD∗∗; Ajay J. Kirtane, MD, SM#; Gregg W. Stone, MD#

Objectives: The authors investigated the relative safety and efficacy of different drug-eluting stents (DES) and bare metal stents (BMS) in patients with ST-segment elevation myocardial infarction (STEMI) using a network meta-analysis.

01 agosto 2013

JACC. Impact of Low Flow on the Outcome of High-Risk Patients Undergoing Transcatheter Aortic Valve Replacement

Florent Le Ven, MD∗; Mélanie Freeman, MD†; John Webb, MD†; Marie-Annick Clavel, DVM, PhD∗; Miriam Wheeler, MD†; Éric Dumont, MD∗; Chris Thompson, MD†; Robert De Larochellière, MD∗; Robert Moss, MD†; Daniel Doyle, MD∗; Henrique B. Ribeiro, MD∗; Marina Urena, MD∗; Luis Nombela-Franco, MD∗; Josep Rodés-Cabau, MD∗; Philippe Pibarot, DVM, PhD∗

Objectives: This study sought to assess the impact of baseline left ventricular (LV) outflow, LV ejection fraction (LVEF), and transvalvular gradient on outcomes following transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis (AS).

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.